Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Core Viewpoint - Purple Biotech Ltd. is advancing its clinical-stage oncology therapies, particularly focusing on CM24 in combination with nivolumab and chemotherapy for treating second-line metastatic pancreatic ductal adenocarcinoma (PDAC) [1][2][3]. Group 1: Event Details - A virtual key opinion leader (KOL) event is scheduled for July 11, 2024, featuring discussions on positive interim data from the Phase 2 study of CM24 [1][2]. - The event will include a live question and answer session following the formal presentation [5]. Group 2: Clinical Data Highlights - The 2024 ASCO Annual Meeting reported data showing reduced risk of death and progression, prolonged overall survival (OS), and progression-free survival (PFS) with the CM24+nivolumab+chemotherapy combination [3]. - The combination therapy demonstrated a higher objective response rate (ORR) and disease control rate (DCR), along with decreasing CA19-9 levels [3]. Group 3: CM24 Mechanism and Development - CM24 is a humanized monoclonal antibody that blocks CEACAM1 interactions, which are involved in tumor immune evasion [3][9]. - Purple Biotech is advancing CM24 as a combination therapy in a Phase 2 study, collaborating with Bristol Myers Squibb for clinical trials [9]. Group 4: Company Overview - Purple Biotech Ltd. is focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes NT219, CM24, and IM1240 [8][9]. - The company is headquartered in Rehovot, Israel, and aims to engage both T cells and NK cells through its innovative therapeutic platforms [9].